A photo of Charles Quinn.

Charles T. Quinn, MD, MS

  • Medical Director, Pediatric Sickle Cell Program
  • Director, Erythrocyte Diagnostic Laboratory
  • Professor, UC Department of Pediatrics

About

Biography

Dr. Quinn conducts patient-oriented and translational research in sickle cell disease and thalassemia. He is the medical director of the Pediatric Sickle Cell Disease Program and the medical director of the Erythrocyte Diagnostic Laboratory at Cincinnati Children’s Hospital. He is also the medical director of the Ohio Department of Health Regional Sickle Cell Services Program – Region 1.

MD: University of Texas Southwestern Medical Center, Dallas, TX, 1994.

MS: University of Texas Southwestern Medical Center, Dallas, TX, 2008.

Residency & Chief Residency: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 1998.

Fellowship: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 2001.

Certifications: Pediatrics, 1998; Pediatric Hematology-Oncology, 2002.

Interests

Sickle cell disease; thalassemia; hemoglobinopathies; genetics of hemoglobinopathies; anemia; autoimmune hemolytic anemia; disorders of red blood cells; iron overload and iron chelation; chronic transfusion therapy; hereditary spherocytosis (HS); hereditary xerocytosis (HX); immune thrombocytopenia (ITP).

Services and Specialties

Cancer and Blood Diseases, Sickle Cell and Hemoglobin Disorders, Cerebrovascular

Interests

Identifying the causes of the cardiomyopathy and nephropathy of sickle cell disease and identifying new treatments for these complications; direct measurement of red blood cell turnover (rate of hemolysis); MRI methods for the quantitation of tissue iron; new agents for immune thrombocytopenia (ITP).

Research Areas

Hematology, Cancer and Blood Diseases

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Selected

Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. Quinn, CT; Niss, O; Dong, M; Pfeiffer, A; Korpik, J; Reynaud, M; Bonar, H; Kalfa, TA; Smart, LR; Malik, P; et al. British Journal of Haematology. 2021; 194:617-625.

Selected

Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity. Alsaied, T; Niss, O; Tretter, JT; Powell, AW; Chin, C; Fleck, RJ; Cnota, JF; Malik, P; Quinn, CT; Nagueh, SM; et al. Scientific Reports. 2020; 10.

Selected

Diastolic dysfunction is associated with exercise impairment in patients with sickle cell anemia. Alsaied, T; Niss, O; Powell, AW; Fleck, RJ; Cnota, JF; Chin, C; Malik, P; Quinn, CT; Taylor, MD. Pediatric Blood and Cancer. 2018; 65.

Selected

Association between diffuse myocardial fibrosis and diastolic dysfunction in sickle cell anemia. Niss, O; Fleck, R; Makue, F; Alsaied, T; Desai, P; Towbin, JA; Malik, P; Taylor, MD; Quinn, CT. Blood. 2017; 130:205-213.

Selected

Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia. Quinn, CT; Smith, EP; Arbabi, S; Khera, PK; Lindsell, CJ; Niss, O; Joiner, CH; Franco, RS; Cohen, RM. American Journal of Hematology. 2016; 91:1195-1201.

Selected

Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology. Bakeer, N; James, J; Roy, S; Wansapura, J; Shanmukhappa, SK; Lorenz, JN; Osinska, H; Backer, K; Huby, A; Shrestha, A; et al. Proceedings of the National Academy of Sciences of the United States of America. 2016; 113:E5182-E5191.

Selected

Cardiomyopathy With Restrictive Physiology in Sickle Cell Disease. Niss, O; Quinn, CT; Lane, A; Daily, J; Khoury, PR; Bakeer, N; Kimball, TR; Towbin, JA; Malik, P; Taylor, MD. JACC: Cardiovascular Imaging. 2016; 9:243-252.

New therapeutics for children with sickle cell disease: A time for celebration, caution, or both?. Quinn, CT; Ware, RE. Pediatric Blood and Cancer. 2022; 69.

Early hydroxyurea use is neuroprotective in children with sickle cell anemia. Karkoska, K; Pfeiffer, A; Beebe, DW; Quinn, CT; Niss, O; McGann, PT. American Journal of Hematology. 2022.

An Immersive Virtual Reality Curriculum for Pediatric Hematology Clinicians on Shared Decision-making for Hydroxyurea in Sickle Cell Anemia. Real, FJ; Hood, AM; Davis, D; Cruse, B; Klein, M; Johnson, Y; McTate, E; Brinkman, WB; Hackworth, R; Hackworth, K; et al. Journal of Pediatric Hematology/Oncology. 2022; 44:e799-e803.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey